Specjalistyczny Gabinet Dermatologiczny Aplikacyjno Badawczy Marek Brzewski Paweł Brzewski s.c.

Research site

Poland ul. Zbozowa 2/25, 30-002, Poland

3 trials recruiting
Psoriasis · Dermatitis atopic · Psoriatic arthropathy
Adults and children

About Specializations

Specjalistyczny Gabinet Dermatologiczny Aplikacyjno Badawczy Marek Brzewski Paweł Brzewski s.c. in Poland specialises in clinical trials of conditions such as Psoriasis, Dermatitis atopic, Psoriatic arthropathy, Alopecia areata, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

ul. Zbozowa 2/2530-002Poland

Open in maps ↗

Recruiting now: 3 trials
Conditions studied: 9

More sites in Poland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

14 clinical trials

Dermatitis atopic

Recruiting

Study of abrocitinib oral suspension for children aged 2 years and older with moderate to severe atopic dermatitis to evaluate long-term safety and effectiveness

InvestigationalNo placebo

Study of abrocitinib oral suspension for children aged 2 years and older with moderate to severe atopic dermatitis to evaluate long-term safety and effectiveness

InvestigationalNo placebo

Poland

Participants:0–17 years
Substances:Abrocitinib
Sponsor:Pfizer Inc.

Contact Research Centre

Psoriatic arthropathy

Recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Previously Used Biologic Treatments

Investigational

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Previously Used Biologic Treatments

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:JNJ-77242113
Sponsor:Janssen Cilag International

Contact Research Centre

Chronic cutaneous lupus erythematosus+2

Recruiting

Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

InvestigationalNo placebo

Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Litifilimab
Sponsor:Biogen Idec Research Limited

Contact Research Centre

Psoriasis

Not yet recruiting

Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

Registered drug

Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Deucravacitinib
Sponsor:Janssen Cilag International

Contact Research Centre

Psoriasis

Not yet recruiting

Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

Registered drug

Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Deucravacitinib
Sponsor:Janssen Cilag International

Contact Research Centre

Alopecia areata

Not recruiting

Study on the Effects of Ritlecitinib in Patients Aged 12 and Older with Alopecia Areata

Investigational

Study on the Effects of Ritlecitinib in Patients Aged 12 and Older with Alopecia Areata

Investigational

Poland

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Pfizer Inc.

Contact Research Centre

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of JNJ-95475939 and Dupilumab for Treating Moderate to Severe Atopic Dermatitis in Adults

Registered drug

Study on the Effectiveness and Safety of JNJ-95475939 and Dupilumab for Treating Moderate to Severe Atopic Dermatitis in Adults

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Dupilumab
Sponsor:Janssen Cilag International

Contact Research Centre

Vitiligo

Not recruiting

Study of ritlecitinib (50 mg and 100 mg daily) compared to placebo in adults with nonsegmental vitiligo

Registered drug

Study of ritlecitinib (50 mg and 100 mg daily) compared to placebo in adults with nonsegmental vitiligo

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Pfizer Inc.

Contact Research Centre

Vitiligo

Not recruiting

Study on the Effects of Upadacitinib in Adults and Adolescents with Non-Segmental Vitiligo Eligible for Systemic Treatment

Investigational

Study on the Effects of Upadacitinib in Adults and Adolescents with Non-Segmental Vitiligo Eligible for Systemic Treatment

Investigational

Poland

Participants:0–17 years · 18–64 years · 65+ years
Substances:Upadacitinib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Treating Moderate to Severe Plaque Psoriasis in Adults

Investigational

Study on the Effectiveness and Safety of JNJ-77242113 for Treating Moderate to Severe Plaque Psoriasis in Adults

Investigational

Poland

Participants:0–17 years · 18–64 years · 65+ years
Substances:JNJ-77242113
Sponsor:Janssen Cilag International

Contact Research Centre

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

Registered drug

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:JNJ-77242113
Sponsor:Janssen Cilag International

Contact Research Centre

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational

Poland

Participants:0–17 years · 18–64 years
Substances:Upadacitinib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites